Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance

MILFORD, Mass., Feb. 26, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of virus infections, today announced that Jonathan P. Freve, CPA, has been appointed Vice President of Finance, a newly created role.  Mr. Freve will be responsible for financial and administrative activities, including financial planning and reporting, accounting and risk management. He reports to Douglas J. Jensen, President and CEO.

Mr. Freve joins the Company with more than 16 years of progressive experience in the life science and technology industries ranging from venture-backed start-ups to publicly traded companies. Prior to joining Spring Bank Pharmaceuticals, he served as the Senior Director of Finance of Santaris Pharma A/S, which was acquired by F. Hoffmann-La Roche Ltd.  Previously, Mr. Freve held controller positions at  two international public companies.  Mr. Freve began his career at the Financial Accounting Standards Board (FASB) and PricewaterhouseCoopers, where he worked in the audit and transaction services practices.  Over his career, Mr. Freve has supported and worked on numerous successful initial public offerings, secondary offerings, mergers and acquisitions, ERP implementations and a variety of complex accounting matters.  Mr. Freve is a certified public accountant in Massachusetts and holds a Bachelor's degree in Business Administration from the University of Massachusetts Amherst.

Douglas J. Jensen, President and CEO, stated, "I am very pleased to welcome Jon Freve to Spring Bank Pharmaceuticals.  Jon is an accomplished financial professional with a proven track record of success and excellent leadership skills. With his strong background in accounting and finance for life sciences and technology companies, I'm very confident that Jon will make many valuable contributions to Spring Bank's continued progress."  

 "I am excited about the unique opportunity to work for Spring Bank Pharmaceuticals, an emerging biotechnology company that I believe has tremendous potential," said Mr. Freve. "I look forward to working with Doug and the team and leading the finance and accounting functions during this period of growth."

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical stage biopharmaceutical company. Based on its proprietary SMNH chemistry platform, Spring Bank is developing a pipeline of products representing a new class of pharmaceuticals with a wide range of applications. These rationally designed molecules combine the selectivity of naturally occurring nucleotides with the drug- like properties of classical pharmaceuticals. The SMNHs have the properties of oral delivery, good pharmacokinetic profile, low side effects and ease of manufacture. The Company's most advanced clinical candidate, SB 9200, is a potential breakthrough drug for the treatment for HBV and other viral diseases. SB 9200 has a novel mechanism of action that involves modulation of the host immune response in the presence of viral infection.

Contact:
Douglas J. Jensen
President and Chief Executive Officer
(508) 473-5993 x105

SOURCE Spring Bank Pharmaceuticals, Inc.

Related Links

http://www.springbankpharm.com